Abstract: In recent years, interest in exploring the potential of Blinatumomab for treatment of B-cell acute lymphoblastic leukemia (B-ALL) at earlier stages has grown. This is because Blinatumomab has shown promising results in the management of refractory/relapsed (R/R) B-ALL and minimal residual disease (MRD). Blinatumomab has shown comparable efficacy to that of conventional chemotherapy as an alternative to consolidation or intensive chemotherapy in pediatric B-ALL patients. Moreover, its use as consolidation therapy or in combination with chemotherapy/targeted therapy, especially in combination with third-generation tyrosine kinase inhibitors (TKIs), shows significant promise for improving prognosis for adult B-ALL patients. This may potentially reduce reliance on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Philadelphia chromosome-positive (Ph⁺) B-ALL patients. Moreover, Blinatumomab is safer, gentler, and more effective than chemotherapy for older adult patients. Effective therapy options are not yet available for infants with KMT2A rearrangement B-ALL; however, preliminary research indicates that Blinatumomab may offer a breakthrough for this subgroup. In this article, we review progress in investigations of Blinatumomab use in newly diagnosed B-ALL patients.